Sistema de Salut de Catalunya
Elez Fernandez, Mª Elena
Chianese, Chiara
Matito Ariza, Judit
Argilés Martinez, Guillem
Garcia Rodriguez, Ariadna
Mulet Margalef, Núria
Tabernero Caturla, Josep
Vivancos Prellezo, Ana
Sanz Garcia, Enrique
Martinelli, Erica
Noguerido Castro, Alba
Mancuso, Francesco Mattia
Caratù, Ginevra
Grasselli, Julieta
Capdevila Castillon, Jaume
Martini, Giulia
Macarulla Mercadé, Teresa
[Elez E, Sanz-García E, Noguerido A, Martini G, Macarulla T, Argilés G, Capdevila J, Garcia A, Tabernero J] Servei d’Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Chianese C, Mancuso FM, Caratù G, Matito J, Vivancos A] Grup de Genòmica del Càncer, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Martinelli E] Medical Oncology, Department of Clinical and Experimental Medicine ‘F. Magrassi’, Università della Campania ‘L. Vanvitelli’, Napoli, Italy. [Grasselli J] Servei d’Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Servei d’Oncologia Mèdica, Institut Català d’Oncologia, L'Hospitalet, Spain. Universitat de Barcelona, L'Hospitalet, Spain. [Mulet N] Servei d’Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. Servei d’Oncologia Mèdica, Institut Català d’Oncologia, L'Hospitalet, Spain. Universitat de Barcelona, L'Hospitalet, Spain.
Vall d'Hebron Barcelona Hospital Campus
2020-01-30T08:40:37Z
2020-01-30T08:40:37Z
2019-07-31
Metastatic colorectal cancer; RAS analysis; Prognostic biomarker
Cáncer colorrectal en metástasis; Análisis RAS; Biomarcador como pronóstico
Càncer colorectal en metàstasi; Anàlisi RAS; Biomarcador com a pronòstic
Despite major advances in the treatment of metastatic colorectal cancer (mCRC), the survival rate remains very poor. This study aims at exploring the prognostic value of RAS‐mutant allele fraction (MAF) in plasma in mCRC. Forty‐seven plasma samples from 37 RAS‐mutated patients with nonresectable metastases were tested for RAS in circulating tumor DNA using BEAMing before first‐ and/or second‐line treatment. RAS MAF was correlated with several clinical parameters (number of metastatic sites, hepatic volume, carcinoembryonic antigen, CA19‐9 levels, primary site location, and treatment line) and clinical outcome [progression‐free survival (PFS) and overall survival (OS)]. An independent cohort of 32 patients from the CAPRI‐GOIM trial was assessed for clinical outcome based on plasma baseline MAF. RAS MAF analysis at baseline revealed a significant correlation with longer OS [Hazard ratios (HR) = 3.514; P = 0.00066]. Patients with lower MAF also showed a tendency to longer PFS, although not statistically significant. Multivariate analysis showed RAS MAFs as an independent prognostic factor in both OS (HR = 2.73; P = 0.006) and first‐line PFS (HR = 3.74; P = 0.049). Tumor response to treatment in patients with higher MAF was progression disease (P = 0.007). Patients with low MAFs at baseline in the CAPRI‐GOIM group also showed better OS [HR = 3.84; 95% confidence intervals (CI) 1.5–9.6; P = 0.004] and better PFS (HR = 2.5; 95% CI: 1.07–5.62; P = 0.033). This minimally invasive test may help in adding an independent factor to better estimate outcomes before initiating treatment. Further prospective studies using MAF as a stratification factor could further validate its utility in clinical practice.
This work was supported partially by the Instituto de Salud Carlos III (Ministerio de Economia y Competitividad) and `Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa' grants [FIS PI12-01589 to RS] and RETICC Cancer.
English
Metàstasi; Citodiagnòstic; Recte - Càncer - Prognosi; DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Neoplasm Staging; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Clinical Laboratory Techniques::Cytological Techniques::Cytodiagnosis::Biopsy::Investigative Techniques::Clinical Laboratory Techniques::Investigative Techniques::Liquid Biopsy; DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Neoplastic Processes::Neoplasm Metastasis; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas de laboratorio clínico::técnicas citológicas::citodiagnóstico::biopsia::técnicas de investigación::técnicas de laboratorio clínico::técnicas de investigación::biopsia líquida; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::estadificación de neoplasias; ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::procesos neoplásicos::metástasis neoplásica
FEBS Press
Molecular Oncology;13(9)
https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.12547
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3375]
